The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

21 articles for L Su


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.EBI
The Scripps Research Institute
Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.EBI
Shandong University
Development of Synthetic Aminopeptidase N/CD13 Inhibitors to Overcome Cancer Metastasis and Angiogenesis.EBI
TBA
Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors.EBI
Shandong University
Novel aminopeptidase N (APN/CD13) inhibitors derived from chloramphenicol amine.EBI
Shandong University
Pyrrolo[2,3-c]azepine derivatives: a new class of potent protein tyrosine phosphatase 1B inhibitors.EBI
Sun Yat-Sen University
Design, synthesis and biological evaluation of novel L-lysine ureido derivatives as aminopeptidase N inhibitors.EBI
Shandong University
Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.EBI
Shandong University
Design and synthesis of novel chloramphenicol amine derivatives as potent aminopeptidase N (APN/CD13) inhibitors.EBI
Shandong University
Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation.EBI
Peking University
Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation.EBI
Peking University
Long Residence Time at the Vasopressin VEBI
Xuzhou Medical University
Benzodiazepine Derivatives as Potent Vasopressin VEBI
Xuzhou Medical University
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.EBI
Peking University
Finding the mechanism of esterase D activation by a small molecule.EBI
Shandong University
Discovery of a small molecule RXFP3/4 agonist that increases food intake in rats upon acute central administration.EBI
Novartis Institutes For Biomedical Research
Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.EBI
Qingdao University
Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim.EBI
University of Pittsburgh
Design and synthesis of biotinylated Hexylselen as a probe to identify KGA allosteric inhibitors by a convenient biomolecular interaction assay.EBI
Zhejiang University
Swinhoeisterols from the South China Sea Sponge Theonella swinhoei.EBI
Second Military Medical University
KAT6 InhibitorsBDB
Beigene Switzerland